Jon W. Johnson

Dr. Jon W. Johnson


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2009 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SKShawn E. Kotermanski
Shawn E. Kotermanski
JJJon W. Johnson
Jon W. Johnson
N-Methyl-d-aspartate receptors (NMDARs) mediate interneuronal communication and are broadly involved in nervous system physiology and pathology (Dingledine et al., 1999). Memantine, a drug that blocks the ion channel formed by NMDARs, is a widely prescribed treatment of Alzheimer's disease (Schmitt, 2005; Lipton, 2006; Parsons et al., 2007). Research on memantine's mechanism of action has focused on the NMDAR subtypes most highly expressed in adult cerebral cortex, NR1/2A and NR1/2B receptors (Cull-Candy and Leszkiewicz, 2004), and has largely ignored interactions with extracellular Mg2+(Mg2+o). Mg2+ois an endogenous NMDAR channel blocker that binds near memantine's binding site (Kashiwagi et al., 2002; Chen and Lipton, 2005). We report that a physiological concentration (1 mm) of Mg2+odecreased memantine inhibition of NR1/2A and NR1/2B receptors nearly 20-fold at a membrane voltage near rest. In contrast, memantine inhibition of the other principal NMDAR subtypes, NR1/2C and NR1/2D receptors, was decreased only ∼3-fold. As a result, therapeutic memantine concentrations should have negligible effects on NR1/2A or NR1/2B receptor activity but pronounced effects on NR1/2C and NR1/2D receptors. Quantitative modeling showed that the voltage dependence of memantine inhibition also is altered by 1 mmMg2+o. We report similar results with the NMDAR channel blocker ketamine, a drug used to model schizophrenia (Krystal et al., 2003). These results suggest that currently hypothesized mechanisms of memantine and ketamine action should be reconsidered and that NR1/2C and/or NR1/2D receptors play a more important role in cortical physiology and pathology than previously appreciated.

9 September 2014 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
NGNathan G. Glasgow
Nathan G. Glasgow
BRBeth Siegler Retchless
Beth Siegler Retchless
JJJon W. Johnson
Jon W. Johnson

15 January 2012 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
BRBeth Siegler Retchless
Beth Siegler Retchless
WGWei Gao
Wei Gao
JJJon W. Johnson
Jon W. Johnson
The authors investigate the basis of the variations in the channel properties of NMDAR subtypes and report that the specificity of the Mg2+ block, the selective permeability to Ca2+ and the single-channel conductance are all primarily controlled by the residue at a single GluN2 site in the M3 transmembrane region. NMDA receptors (NMDARs) are glutamate-gated ion channels that are present at most excitatory mammalian synapses. The four GluN2 subunits (GluN2A–D) contribute to four diheteromeric NMDAR subtypes that have divergent physiological and pathological roles. Channel properties that are fundamental to NMDAR function vary among subtypes. We investigated the amino acid residues responsible for variations in channel properties by creating and examining NMDARs containing mutant GluN2 subunits. We found that the NMDAR subtype specificity of three crucial channel properties, Mg2+ block, selective permeability to Ca2+ and single-channel conductance, were all controlled primarily by the residue at a single GluN2 site in the M3 transmembrane region. Mutant cycle analysis guided by molecular modeling revealed that a GluN2-GluN1 subunit interaction mediates the site's effects. We conclude that a single GluN2 subunit residue couples with the pore-forming loop of the GluN1 subunit to create naturally occurring variations in NMDAR properties that are critical to synaptic plasticity and learning.

1 February 2015 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
JJJon W. Johnson
Jon W. Johnson
NGNathan G Glasgow
Nathan G Glasgow
NPNadezhda V Povysheva
Nadezhda V Povysheva

6 September 2017 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
NGNathan G. Glasgow
Nathan G. Glasgow
NPNadezhda V. Povysheva
Nadezhda V. Povysheva
AAAndrea M. Azofeifa
Andrea M. Azofeifa
JJJon W. Johnson
Jon W. Johnson
Memantine and ketamine are clinically useful NMDA receptor (NMDAR) open channel blockers that inhibit NMDARs with similar potency and kinetics, but display vastly different clinical profiles. This discrepancy has been hypothesized to result from inhibition by memantine and ketamine of overlapping but distinct NMDAR subpopulations. For example, memantine but not ketamine may inhibit extrasynaptic NMDARs more effectively than synaptic NMDARs. However, the basis for preferential NMDAR inhibition depending on subcellular location has not been investigated systematically. We integrated recordings from heterologously expressed single NMDAR subtypes, kinetic modeling, and recordings of synaptically evoked NMDAR responses in acute brain slices to investigate mechanisms by which channel blockers may distinguish NMDAR subpopulations. We found that memantine and ketamine differentially alter NMDAR desensitization and that memantine stabilizes a Ca2+-dependent desensitized state. As a result, inhibition by memantine of GluN1/2A receptors in tsA201 cells and of native synaptic NMDARs in cortical pyramidal neurons from mice of either sex increased in conditions that enhanced intracellular Ca2+accumulation. Therefore, differential inhibition by memantine and ketamine based on NMDAR location is likely to result from location dependence of the intensity and duration of NMDAR activation. Modulation of Ca2+-dependent NMDAR desensitization is an unexplored mechanism of inhibitory action with the potential to endow drugs with NMDAR selectivity that leads to superior clinical profiles. Our results suggest that designing compounds to target specific receptor states, rather than specific receptor types, may be a viable strategy for future drug development.SIGNIFICANCE STATEMENTMemantine and ketamine are NMDA receptor (NMDAR) channel-blocking drugs with divergent clinical effects. Understanding mechanistically their differential actions may advance our understanding of nervous system disorders and suggest strategies for the design of more effective drugs. Here, we show that memantine and ketamine have contrasting effects on NMDAR desensitization. Ketamine binding decreases occupancy of desensitized states of the GluN1/2B NMDAR subtype. In contrast, memantine binding increases occupancy of GluN1/2A and native NMDAR desensitized states entered after accumulation of intracellular Ca2+, a novel inhibitory mechanism. These properties may contribute to inhibition of distinct NMDAR subpopulations by memantine and ketamine and help to explain their differential clinical effects. Our results suggest stabilization of Ca2+-dependent desensitized states as a new strategy for pharmaceutical neuroprotection.

29 September 2009 in The Journal of Physiology
Verified
Journal Article
Closed access
SKShawn E. Kotermanski
Shawn E. Kotermanski
JWJesse T. Wood
Jesse T. Wood
JJJon W. Johnson
Jon W. Johnson